TrialClinics (Sao Paulo, Brazil)2009

Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen.

Luis Mauro Alvim de Lima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.